Drug interactions profile of Oral Antineoplastic Agents (OAAs) dispensed for oncologic patients
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/5369 |
Resumo: | The present study aims to list the oral antineoplastic agents (OAAs) most dispensed in an oncology hospital, identifying their doses, indications, contraindications and possible drug interactions (DIs). Documentary, retrospective, analytical and descriptive study, where OAAs dispensation spreadsheets were analyzed, from january to july 2019. Data were obtained from Micromedex® and analyzed by SPSS® (version 20) using descriptive statistics. 22 types of OAAs were dispensed, making a total of 360.703 drugs. Anastrozole was the most prescribed (51,85%) and hormone therapy agents (32%) were considered the main group. Tyrosine kinase inhibitors exposed the highest rates of contraindications (n=64). With regard to serious risk interactions, nilotinib (n=264), dasatinib (n=182) and metotrexate (n=134) were the drugs with the highest number of reports. The OAAs that did not present any type of interaction were anastrozole and diethylstilbestrol. Of the pharmacological agents that most interacted with OAAs, live vaccines (n=11) were the most present in contraindications and warfarin was the one that had the highest rate of serious interactions (n=8). As for the repercussions of DIs, the most frequent indices were the increased risk of prolongation of the QT interval (n=67) and increased exposure to a drug (n=51). Bearing in mind that cancer therapy requires special attention because of the possible interactions with OAAs, these results are shown to be a useful tool for the entire multiprofessional health team, especially the pharmacist, who has an essential role in the pharmaceutical assistance service on an outpatient basis. |
id |
UNIFEI_ff697860b455085423e70c96af92d9f5 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/5369 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Drug interactions profile of Oral Antineoplastic Agents (OAAs) dispensed for oncologic patientsPerfil de interacciones farmacológicas de los Agentes Antineoplásicos Orales (AAOs) dispensados para pacientes con cáncerPerfil de interações medicamentosas de Agentes Antineoplásicos Orais (AAOs) dispensados para pacientes oncológicosNeoplasiasAntineoplásicosAdministração oralInterações medicamentosas.NeoplasiasAntineoplásicosAdministración oralInteracciones farmacológicas.NeoplasmsAntineoplastic agentsAdministrationoralDrug interactions.The present study aims to list the oral antineoplastic agents (OAAs) most dispensed in an oncology hospital, identifying their doses, indications, contraindications and possible drug interactions (DIs). Documentary, retrospective, analytical and descriptive study, where OAAs dispensation spreadsheets were analyzed, from january to july 2019. Data were obtained from Micromedex® and analyzed by SPSS® (version 20) using descriptive statistics. 22 types of OAAs were dispensed, making a total of 360.703 drugs. Anastrozole was the most prescribed (51,85%) and hormone therapy agents (32%) were considered the main group. Tyrosine kinase inhibitors exposed the highest rates of contraindications (n=64). With regard to serious risk interactions, nilotinib (n=264), dasatinib (n=182) and metotrexate (n=134) were the drugs with the highest number of reports. The OAAs that did not present any type of interaction were anastrozole and diethylstilbestrol. Of the pharmacological agents that most interacted with OAAs, live vaccines (n=11) were the most present in contraindications and warfarin was the one that had the highest rate of serious interactions (n=8). As for the repercussions of DIs, the most frequent indices were the increased risk of prolongation of the QT interval (n=67) and increased exposure to a drug (n=51). Bearing in mind that cancer therapy requires special attention because of the possible interactions with OAAs, these results are shown to be a useful tool for the entire multiprofessional health team, especially the pharmacist, who has an essential role in the pharmaceutical assistance service on an outpatient basis.El presente estudio tiene como objetivo enumerar los agentes antineoplásicos orales (AAOs) más dispensados en un hospital de oncología, identificando sus dosis, indicaciones, contraindicaciones y posibles interacciones farmacológicas (IFs). Estudio documental, retrospectivo, analítico y descriptivo, donde se analizaron las hojas de cálculo de dispensación de AAOs, de enero a julio de 2019. Los datos se obtuvieron de Micromedex® y se analizaron mediante SPSS® (versión 20) utilizando estadísticas descriptivas. Se dispensaron 22 tipos de AAOs, lo que hace un total de 360.703 medicamentos. El anastrozol fue el más recetado (51,85%) y los agentes de terapia hormonal (32%) se consideraron el grupo principal. Los inhibidores de la tirosina quinasa expusieron las tasas más altas de contraindicaciones (n=64). Con respecto a las interacciones de riesgo graves, nilotinib (n=264), dasatinib (n=182) y metotrexato (n=134) fueron los fármacos con el mayor número de informes. Los AAOs que no presentaron ningún tipo de interacción fueron anastrozol y dietilestilbestrol. De los agentes farmacológicos que interactuaron más con los AAOs, las vacunas vivas (n = 11) fueron las más presentes en las contraindicaciones y la warfarina fue la que tuvo la tasa más alta de interacciones graves (n=8). En cuanto a las repercusiones de los IFs, los índices más frecuentes fueron el mayor riesgo de prolongación del intervalo QT (n=67) y la mayor exposición a un fármaco (n=51). Teniendo en cuenta que la terapia contra el cáncer requiere una atención especial debido a las posibles interacciones con AAOs, estos resultados son una herramienta útil para todo el equipo de salud multiprofesional, especialmente el farmacéutico, que desempeña un papel esencial en el servicio de asistencia farmacéutica de forma ambulatoria.O presente estudo visa elencar os agentes antineoplásicos orais (AAOs) mais dispensados em um hospital oncológico, identificando suas doses, indicações, contraindicações e possíveis interações medicamentosas (IMs). Estudo documental, retrospectivo, analítico e descritivo, onde foram analisadas planilhas de dispensação de AAOs, no período de janeiro a julho de 2019. Os dados foram obtidos do Micromedex® e analisados pelo SPSS® (versão 20) mediante estatística descritiva. Foram dispensados 22 tipos de AAOs, perfazendo um total de 360.703 fármacos. O anastrozol foi o mais prescrito (51,85%) e os agentes hormonioterápicos (32%) foram considerados o principal grupo. Os inibidores da tirosina quinase expuseram os maiores índices de contraindicações (n=64). Com relação às interações de risco grave, o nilotinibe (n=264), o dasatinibe (n=182) e o metotrexato (n=134) foram os fármacos com maior número de relatos. Os AAOs que não apresentaram nenhum tipo de interação foram o anastrozol e o dietilestilbestrol. Dos agentes farmacológicos que mais interagiram com os AAOs, as vacinas vivas (n=11) foram as mais presentes nas contraindicações e a varfarina a que deteve maior índice de interações graves (n=8). Quanto às repercussões das IMs, os índices mais frequentes foram o risco aumentado do prolongamento do intervalo QT (n=67) e aumento da exposição a um fármaco (n=51). Tendo em vista que a terapia oncológica requer uma atenção especial por conta das possíveis interações com AAOs, tais resultados se mostram como uma ferramenta útil à toda equipe multiprofissional de saúde, principalmente ao farmacêutico, que possui papel essencial no serviço de assistência farmacêutica em nível ambulatorial.Research, Society and Development2020-06-28info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/536910.33448/rsd-v9i8.5369Research, Society and Development; Vol. 9 No. 8; e145985369Research, Society and Development; Vol. 9 Núm. 8; e145985369Research, Society and Development; v. 9 n. 8; e1459853692525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/5369/4597Copyright (c) 2020 Herlem Silva Rodrigues, Railson Pereira Souza, Renata Rodrigues de Oliveira Castelo Branco, Layane Carneiro Alves Pereira, Rayran Walter Ramos de Sousa, Maria Helena Rodrigues Mesquita Brittoinfo:eu-repo/semantics/openAccessRodrigues, Herlem SilvaSouza, Railson PereiraSousa, Rayran Walter Ramos dePereira, Layane Carneiro AlvesBranco, Renata Rodrigues de Oliveira CasteloSilveira, Pedro Henrique Fernandes PaivaBritto, Maria Helena Rodrigues Mesquita2020-08-20T18:00:17Zoai:ojs.pkp.sfu.ca:article/5369Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:28:54.302843Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Drug interactions profile of Oral Antineoplastic Agents (OAAs) dispensed for oncologic patients Perfil de interacciones farmacológicas de los Agentes Antineoplásicos Orales (AAOs) dispensados para pacientes con cáncer Perfil de interações medicamentosas de Agentes Antineoplásicos Orais (AAOs) dispensados para pacientes oncológicos |
title |
Drug interactions profile of Oral Antineoplastic Agents (OAAs) dispensed for oncologic patients |
spellingShingle |
Drug interactions profile of Oral Antineoplastic Agents (OAAs) dispensed for oncologic patients Rodrigues, Herlem Silva Neoplasias Antineoplásicos Administração oral Interações medicamentosas. Neoplasias Antineoplásicos Administración oral Interacciones farmacológicas. Neoplasms Antineoplastic agents Administration oral Drug interactions. |
title_short |
Drug interactions profile of Oral Antineoplastic Agents (OAAs) dispensed for oncologic patients |
title_full |
Drug interactions profile of Oral Antineoplastic Agents (OAAs) dispensed for oncologic patients |
title_fullStr |
Drug interactions profile of Oral Antineoplastic Agents (OAAs) dispensed for oncologic patients |
title_full_unstemmed |
Drug interactions profile of Oral Antineoplastic Agents (OAAs) dispensed for oncologic patients |
title_sort |
Drug interactions profile of Oral Antineoplastic Agents (OAAs) dispensed for oncologic patients |
author |
Rodrigues, Herlem Silva |
author_facet |
Rodrigues, Herlem Silva Souza, Railson Pereira Sousa, Rayran Walter Ramos de Pereira, Layane Carneiro Alves Branco, Renata Rodrigues de Oliveira Castelo Silveira, Pedro Henrique Fernandes Paiva Britto, Maria Helena Rodrigues Mesquita |
author_role |
author |
author2 |
Souza, Railson Pereira Sousa, Rayran Walter Ramos de Pereira, Layane Carneiro Alves Branco, Renata Rodrigues de Oliveira Castelo Silveira, Pedro Henrique Fernandes Paiva Britto, Maria Helena Rodrigues Mesquita |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Rodrigues, Herlem Silva Souza, Railson Pereira Sousa, Rayran Walter Ramos de Pereira, Layane Carneiro Alves Branco, Renata Rodrigues de Oliveira Castelo Silveira, Pedro Henrique Fernandes Paiva Britto, Maria Helena Rodrigues Mesquita |
dc.subject.por.fl_str_mv |
Neoplasias Antineoplásicos Administração oral Interações medicamentosas. Neoplasias Antineoplásicos Administración oral Interacciones farmacológicas. Neoplasms Antineoplastic agents Administration oral Drug interactions. |
topic |
Neoplasias Antineoplásicos Administração oral Interações medicamentosas. Neoplasias Antineoplásicos Administración oral Interacciones farmacológicas. Neoplasms Antineoplastic agents Administration oral Drug interactions. |
description |
The present study aims to list the oral antineoplastic agents (OAAs) most dispensed in an oncology hospital, identifying their doses, indications, contraindications and possible drug interactions (DIs). Documentary, retrospective, analytical and descriptive study, where OAAs dispensation spreadsheets were analyzed, from january to july 2019. Data were obtained from Micromedex® and analyzed by SPSS® (version 20) using descriptive statistics. 22 types of OAAs were dispensed, making a total of 360.703 drugs. Anastrozole was the most prescribed (51,85%) and hormone therapy agents (32%) were considered the main group. Tyrosine kinase inhibitors exposed the highest rates of contraindications (n=64). With regard to serious risk interactions, nilotinib (n=264), dasatinib (n=182) and metotrexate (n=134) were the drugs with the highest number of reports. The OAAs that did not present any type of interaction were anastrozole and diethylstilbestrol. Of the pharmacological agents that most interacted with OAAs, live vaccines (n=11) were the most present in contraindications and warfarin was the one that had the highest rate of serious interactions (n=8). As for the repercussions of DIs, the most frequent indices were the increased risk of prolongation of the QT interval (n=67) and increased exposure to a drug (n=51). Bearing in mind that cancer therapy requires special attention because of the possible interactions with OAAs, these results are shown to be a useful tool for the entire multiprofessional health team, especially the pharmacist, who has an essential role in the pharmaceutical assistance service on an outpatient basis. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-06-28 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/5369 10.33448/rsd-v9i8.5369 |
url |
https://rsdjournal.org/index.php/rsd/article/view/5369 |
identifier_str_mv |
10.33448/rsd-v9i8.5369 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/5369/4597 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 9 No. 8; e145985369 Research, Society and Development; Vol. 9 Núm. 8; e145985369 Research, Society and Development; v. 9 n. 8; e145985369 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052803021012992 |